This post is the fifth in our five-part series, Navigating Life Sciences Transactions, where our team of attorneys provides essential strategies and insights for successful life sciences transactions.

The life sciences industry represents a massive and highly nuanced opportunity for startups. Pharma alone is projected to cross $1.6 trillion by 2030, and healthcare AI is growing at a CAGR of over 40 ...

Real-time batch monitoring powered by machine learning is helping manufacturers detect deviations early to reduce failures, improve consistency and cut costs. By simulating cell and gene therapy ...

The Delaware Supreme Court’s Jan. 12, 2026, decision in Johnson & Johnson v. Fortis Advisors provides important insights for buyers who use earnouts in structuring their acquisitions, a common ...

The Board on Life Sciences (BLS) was established in 1984 to serve as the focal point for addressing critical, emerging policy and technical issues associated with the life sciences and biotechnology ...